Dental Sleep Medicine

A clinically proven answer to snoring and sleep apnea.

Oniris Plus is a thermoformable mandibular advancement device, FDA cleared and as effective as custom-made devices in a randomized controlled trial.

Discover Oniris Plus See clinical results

How it works

More comfort. More resistance. More adjustment.

Oniris Plus mandibular advancement device

Bi-block thermoformable design

Splittable posterior extensions

Optimal coverage adapted to each patient, reducing joint discomfort.
Strengthened connecting hooks

Increased titration capacity from 0 to 11 mm, suitable for bruxism patients.
Precise dental coverage

Bi-material design for customized adaptation and enhanced comfort.

Clinical results

Clinically proven efficacy.

Two independent clinical studies confirm Oniris efficacy : the Marty 2017 pilot study and the IRIS 2019 randomized controlled trial (Thorax, Editor's Choice).

69 %

Responder rate

77.3% in moderate OSA patients (Marty 2017)

62 %

AHI reduction

From 34.1 to 12.8 events per hour (Marty 2017)

93.1 %

Compliance at 12 months

Good or excellent adherence (IRIS 2019)

96.6 %

Safety profile

No significant dental or joint impact at 1 year (IRIS 2019)

IRIS Study : Oniris vs custom-made MAD

The largest randomized controlled trial in the MAD field : 200+ patients, 7 centers, 12-month follow-up. Both devices showed comparable AHI reduction sustained over 12 months.

Non-inferiority confirmed in both ITT and Per-Protocol analyses, regardless of gender, BMI or OSA severity. Combined with Marty 2017 pilot results, Oniris demonstrates strong efficacy across patient profiles.

Marty M, Lacaze O, Arreto CD, et al. J Prosthodont 2017 ; 26 : 381-386.
Pépin JL, Raymond N, Lacaze O, et al. Thorax 2019 ; 74 : 667-674.

Market

A massive, underserved market.

Oniris Plus fills a structural gap in the US sleep care continuum, from snoring to severe OSA with CPAP intolerance.

Oniris Plus pack : box, device and instructions

Oniris Plus complete pack

A huge market, poorly served

30M+ Americans with sleep apnea¹
90M+ snorers, including 37M regular²
80% of OSA cases undiagnosed
50% abandon CPAP within the first year³

Current solutions fall short

CPAP : effective, but low adherence
Custom MAD : effective, but slow and costly
OTC devices : accessible, but underperforming

Oniris Plus fills the gap

FDA cleared for OTC + Rx use
Efficacy comparable to custom-made (RCT)
Thermoformable, fitted by patient or dentist as a complement to custom devices
Snorers, mild/moderate OSA, severe with CPAP intolerance
Immediately available